A new approach in underwriting high-cost drugs
In recent years, private drug plan sponsors have been faced with a serious issue: an increase in the number of covered individuals claiming very high-cost drugs for several years. The impact on private plans is significant and is even threatening their sustainability.
- December 6, 2013 September 13, 2019
- 10:39